País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
PROCHLORPERAZINE MESILATE
Mercury Pharmaceuticals (Ireland) Ltd
PROCHLORPERAZINE MESILATE
12.5 Mg/Ml
Solution for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Prochlorperazine Injection BP 12.5mg/ml. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1ml of solution contains 12.5mg (1.25% w/v) of Prochlorperazine Mesilate BP. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Colourless or almost colourless sterile solution for injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the symptomatic treatment of acute vertigo such as is associated with Meniere's syndrome, and for nausea and vomiting from whatever cause including that associated with migraine. It is also used in the management of schizophrenia, acute mania, phobias and similar psychotic reactions, and as an adjunct to the short term management of anxiety. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Prochlorperazine Injection is for administration by deep intramuscular injection. Adults: Meniere's syndrome, nausea and vomiting: 12.5mg by deep IM injection followed by oral medication six hours later, if necessary. Schizophrenia and other psychotic disorders: 12.5 to 25mg two or three times a day by deep IM injection until oral treatment becomes possible. Intramuscular prochlorperazine should not be administered to children. Elderly: Prochlorperazine should be used with caution in the elderly. Because elderly patients are susceptible to centrally-acting drugs, lower initial dosage is recommended. Correct initial diagnosis of the disorder is important. Care should also be taken not to confuse adverse effects of prochlorperazine e.g. orthostatic hypotension with effects due to the primary disorder. 4.3 CONTRAINDICATIONS Prochlorperazine should not be administered to patients who are known to be hypersensitive to the active ingredient. IRISH MEDICINES BOARD ________________________________________________ Leer el documento completo